Mineralys Therapeutics (MLYS) Total Liabilities (2022 - 2026)

Mineralys Therapeutics has reported Total Liabilities for 5 years, with the latest figure at $652.9 million in Q1 2026.

• Quarterly Total Liabilities rose 83.94% year-over-year to $652.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $652.9 million (up 83.94% YoY) and the FY2025 annual result came in at $661.8 million, up 221.42% from the prior year.
• Total Liabilities fell to $652.9 million in Q1 2026 per MLYS's latest filing, from $661.8 million in the prior quarter.
• Over five years, Total Liabilities peaked at $661.8 million in Q4 2025 and troughed at $114.4 million in Q4 2022.
• A 5-year average of $356.2 million and a median of $312.5 million in 2023 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2024 and 2025: Total Liabilities retreated 18.17% in 2024, then jumped 221.42% in 2025.
• Over 5 years, Total Liabilities stood at $114.4 million in 2022, then surged by 119.88% to $251.6 million in 2023, then dropped by 18.17% to $205.9 million in 2024, then surged by 221.42% to $661.8 million in 2025, then declined by 1.35% to $652.9 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $652.9 million, $661.8 million, and $599.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.